Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
ORGANIZATION
Teva Takeda CEO Named Chairman of Established Drugs’ Group
The Japan Established Medicine Association (JEMA) has appointed Teva Takeda Pharma CEO Hiroshi Matsumori, who has spearheaded the group’s launch, as its first chairman for an unspecified term of office. The appointment was endorsed by a unanimous vote from JEMA…
To read the full story
Related Article
- Established Drugs’ Group Boots Up with 6 Firms Plus One Organization
September 14, 2021
- New Established Medicines’ Association to Discuss Info Transfer Rules for LLP Withdrawals
August 20, 2021
- New Established Drugs’ Group Places Top Priority on Stable Generic Supply; Research-Driven and Foreign Firms to Join
August 20, 2021
- New Trade Group for Established Drugs to Launch in Japan
July 13, 2021
ORGANIZATION
- EFPIA Executive Hails Japan’s Honebuto as “Blueprint” for Europe
August 17, 2026
- New Chuikyo Pharmacist Rep Urges 2027 Revision to Stay within 4-Minister Deal
August 3, 2026
- Ectopic Fat Research Group Launches to Push Cross-Disciplinary Studies
July 31, 2026
- JPMA Chief Seeks Concrete Reforms to Reward Innovation after Honebuto
July 31, 2026
- Patient Groups Launch Consortium to Improve Access to Drug Information
July 31, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…